In particular, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists with proven cardiovascular and renal benefits are prioritized for patients with established ASCVD, HF, or CKD independent of baseline HbA1c or metformin use. The gene discussed is SLC5A2; the disease is chronic kidney disease.